Israeli, US Firms Create AI Program To Spot Lung Disease Risks

Israeli and US medtech companies have teamed up to create a program that uses artificial intelligence to identify patients at high risk for respiratory or pulmonary diseases such as lung cancer. 

The LungFlag AlgoMarker, which analyzes data from a patient’s electronic health record, is a collaboration between Medial EarlySign, a Hod Hasharon-based company that develops clinical predictive analytics, and Geisinger, an integrated healthcare system from Pennsylvania. 

Working with Geisinger, Medial EarlySign developed the program to facilitate earlier invention, which is a key feature of the American healthcare provider’s care model as it helps improve clinical outcomes, creates higher patient satisfaction and reduces medical costs. 

“Our work with Medial EarlySign is helping us to address some of healthcare’s most pressing issues and provide exceptional outcomes for our patients,” said David Vawdrey, Ph.D., chief data informatics officer for Geisinger. 

“We share their evidence-based approach to developing and evaluating predictive models to benefit patient care,” he said. 

“By introducing predictive AI into clinical workflows and creating personalized value-based care, we are making significant strides to address and assist the improvement of lung cancer screening efforts and to increase early detection and participation,” said Ori Geva, chief executive officer and co-founder of EarlySign. 

“We are honored to work with Geisinger to bring forth solutions that identify and enrich subpopulations who could benefit from earlier treatment and to identify and prioritize patients when interventions stand more chance of halting or preventing the serious complications from the onset of lung disease.”